2 weeks Ago By ABMN Staff
Legal & General Group Plc trimmed its position in shares of Celldex Therapeutics, Inc. ( NASDAQ:CLDX – Free Report ) by 6.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 64,334 shares of the biopharmaceutical company’s stock after selling 4,209 shares during the period. Legal & General Group Plc owned approximately 0.10% of Celldex Therapeutics worth $1,626,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC increased its position in shares of Celldex Therapeutics by 215.7% during the fourth quarter.
EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the period. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the fourth quarter worth $81,000. KBC Group NV increased its holdings in Celldex Therapeutics by 79.
1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,647 shares during the period. AlphaQuest LLC raised its stake in shares of Celldex Therapeutics by 171.
0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares in the last quarter. Finally, Aristides Capital LLC bought a new position in shares of Celldex Therapeutics during the 4th quarter worth about $202,000.
Analyst Ratings Changes Several research analysts recently issued reports on CLDX shares. The Goldman Sachs Group dropped their price target on shares of Celldex Therapeutics from $42.00 to $36.
00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th.
Morgan Stanley initiated coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 target price for the company.
HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th.
They set a “buy” rating and a $44.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock.
Based on data from MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $54.33. Celldex Therapeutics Stock Performance Shares of CLDX stock opened at $19.
57 on Friday. The stock’s fifty day moving average is $19.21 and its 200-day moving average is $23.
53. Celldex Therapeutics, Inc. has a 52 week low of $14.
40 and a 52 week high of $47.00. The stock has a market capitalization of $1.
30 billion, a PE ratio of -7.61 and a beta of 1.59.
Celldex Therapeutics ( NASDAQ:CLDX – Get Free Report ) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.
73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.
32% and a negative return on equity of 19.75%. The company had revenue of $1.
18 million during the quarter, compared to the consensus estimate of $1.25 million. As a group, analysts forecast that Celldex Therapeutics, Inc.
will post -2.48 earnings per share for the current fiscal year. About Celldex Therapeutics ( Free Report ) Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. Further Reading Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
